Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.7, 2012-07, pp. : 921-947

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies

By Korycka-Wołowiec Anna Robak Tadeusz

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 11, 2012-11 ,pp. : 1455-1468

Informa Healthcare

Access to resources Recommend Favorite

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

By Winer Eric S Ingham Randall R Castillo Jorge J

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 355-361

Informa Healthcare

Access to resources Recommend Favorite

Cell Death Targeting Therapies in B Lymphoid Malignancies

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 769-780

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

By Prada Patricia O

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 751-763

Informa Healthcare

Access to resources Recommend Favorite

Structure-based Drugs Design Studies on Spleen Tyrosine Kinase Inhibitors

Letters in Drug Design & Discovery, Vol. 13, Iss. 9, 2016-11 ,pp. : 845-858

Bentham Science Publishers

Access to resources Recommend Favorite